Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleBasic Science Investigation

Impact of 18F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry

Bruce E. Hillner, Barry A. Siegel, Lucy Hanna, Fenghai Duan, Anthony F. Shields and R. Edward Coleman
Journal of Nuclear Medicine February 2014, jnumed.113.130005; DOI: https://doi.org/10.2967/jnumed.113.130005
Bruce E. Hillner
1Department of Internal Medicine and the Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barry A. Siegel
2Division of Nuclear Medicine, Mallinckrodt Institute of Radiology and the Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucy Hanna
3Department of Biostatistics and Center for Statistical Sciences, Brown University, Providence, Rhode Island
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fenghai Duan
3Department of Biostatistics and Center for Statistical Sciences, Brown University, Providence, Rhode Island
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony F. Shields
4Karmanos Cancer Institute, Wayne State University, Detroit, Michigan; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Edward Coleman
5Department of Radiology, Duke University School of Medicine, Durham, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Abstract

Under Medicare’s Coverage with Evidence Development policy, PET using 18F-sodium fluoride (NaF PET) to identify osseous metastasis became a covered service if prospective registry data were collected. The National Oncologic PET Registry (NOPR) developed a NaF PET registry built on the foundation of its prior registry for PET with 18F-FDG. Men with prostate cancer represented 72% of the cases. Methods: Prospective data before and after NaF PET were collected from referring and interpreting physicians. The analysis set consisted of consenting men age 65 y or older with prostate cancer undergoing NaF PET for initial staging (IS, n = 1,024), suspected first osseous metastasis (FOM, n = 1,997), or suspected progression of osseous metastasis (POM, n = 510). Results: Referring physicians indicated that if NaF PET were not available, other advanced imaging (body CT, MR imaging, or 18F-FDG PET) would be their plan in about half of the cases. After NaF PET, the postimaging plan was revised to treatment in 77%, 52%, and 71% for IS, FOM, and POM, respectively. When intended management was classified as either treatment or nontreatment, the overall change in intended management ranged from 44% to 52% and from 12% to 16% if no effect was assumed for those cases with pre-PET plans for other imaging (imaging-adjusted impact). Interpreting physicians recorded definite findings of bone metastasis in 14%, 29%, and 76% for IS, FOM, and POM, respectively. The intended care patterns varied widely across indication and scan abnormality category combinations. Conclusion: NaF PET has high overall impact, principally related to its effect on replacing intended use of other advanced imaging. Its imaging-adjusted impact was similar to that observed with 18F-FDG PET for restaging or suspected recurrence in other cancer types.

  • PET
  • prostate cancer
  • registry
  • bone scintigraphy
  • prospective studies

Footnotes

  • ↵† Deceased.

  • Published online ▪▪▪▪▪▪▪▪▪▪▪▪.

  • © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Next
Back to top

In this issue

Journal of Nuclear Medicine: 63 (5)
Journal of Nuclear Medicine
Vol. 63, Issue 5
May 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of 18F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Impact of 18F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry
Bruce E. Hillner, Barry A. Siegel, Lucy Hanna, Fenghai Duan, Anthony F. Shields, R. Edward Coleman
Journal of Nuclear Medicine Feb 2014, jnumed.113.130005; DOI: 10.2967/jnumed.113.130005

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Impact of 18F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry
Bruce E. Hillner, Barry A. Siegel, Lucy Hanna, Fenghai Duan, Anthony F. Shields, R. Edward Coleman
Journal of Nuclear Medicine Feb 2014, jnumed.113.130005; DOI: 10.2967/jnumed.113.130005
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PET/CT with Sodium 18F-Fluoride for Management of Patients with Prostate Cancer
  • PubMed
  • Google Scholar

Cited By...

  • 18F-NaF PET/CT of Obese Patients on a Lutetium-Yttrium Oxyorthosilicate PET/CT System: Patient Dosimetry, Optimization of Injected Activity, and Acquisition Time
  • Molecular Imaging of Bone Metastases and Their Response to Therapy
  • Observer Agreement and Accuracy of 18F-Sodium Fluoride PET/CT in the Diagnosis of Bone Metastases in Prostate Cancer
  • 18F-Sodium Fluoride PET: History, Technical Feasibility, Mechanism of Action, Normal Biodistribution, and Diagnostic Performance in Bone Metastasis Detection Compared with Other Imaging Modalities
  • No Added Value of 18F-Sodium Fluoride PET/CT for the Detection of Bone Metastases in Patients with Newly Diagnosed Prostate Cancer with Normal Bone Scintigraphy
  • Intended Versus Inferred Treatment After 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry
  • The Injustice of Being Judged by the Errors of Others: The Tragic Tale of the Battle for PET Reimbursement
  • Anatomic and Molecular Imaging in Prostate Cancer
  • Hospice Admission and Survival After 18F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry
  • Prospective Study Evaluating Na18F PET/CT in Predicting Clinical Outcomes and Survival in Advanced Prostate Cancer
  • Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT
  • 18F-Fluoride PET in the Assessment of Malignant Bone Disease
  • Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival
  • 18F-Fluoride PET Used for Treatment Monitoring of Systemic Cancer Therapy: Results from the National Oncologic PET Registry
  • Impact of 18F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry
  • PET/CT with Sodium 18F-Fluoride for Management of Patients with Prostate Cancer
  • Google Scholar

More in this TOC Section

  • Repeatability of 68Ga-PSMA-HBED-CC PET/CT–Derived Total Molecular Tumor Volume
  • Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM
  • First In Vivo and Phantom Imaging of Cyclotron-Produced 133La as a Theranostic Radionuclide for 225Ac and 135La
Show more Basic Science Investigation

Similar Articles

Keywords

  • PET
  • prostate cancer
  • registry
  • bone scintigraphy
  • prospective studies
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire